Analysts found the agency's decision to cancel the meeting encouraging. Elsewhere, the Novo Holdings-owned CDMO cut about 350 ...

The two trading partners documented provisions of a deal that would set a 15% tariff on many EU imports, including cars, auto ...

The deal gives Gilead ownership of a technology that can genetically modify immune cells inside the body, an approach could potentially widen access to CAR-T treatment.

Dawnzera is the third medicine cleared by U.S. regulators this year for the rare genetic condition, and the second wholly owned medicine Ionis has brought to market.

A refinancing deal will delay the maturity of $700 million in debt until 2030, allowing the company to “fully fund” its ...

RFK Jr. has his sights set on increasing oversight and enforcement against drugmakers that run afoul of advertising laws.

Anne White, a 30-year company veteran who previously led the company’s oncology unit, will step down as head of Lilly ...

The company plans to continue with a lower dose and a change in the pre-treatment regimen after a trial participant died ...

Xoma, a drug royalty specialist, buys another ‘zombie’ biotech A deal to acquire Alkermes spinout Mural Oncology is Xoma’s fourth since June and is the latest evidence of interest in buying and ...

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

On an earnings call, CSL CEO Paul McKenzie described weakness in the U.S. market for seasonal flu vaccines as “disappointing” ...

The FDA said data for PTC's drug did not prove "substantial evidence of efficacy." Elsewhere, the FDA delayed its decision on ...